Clinical Trial Detail

NCT ID NCT00780494
Title Ph II of Capecitabine, Carboplatin and Bevacizumab for Gastroesophageal Junction and Gastric Carcinoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Pamela L. Kunz
Indications

gastroesophageal junction adenocarcinoma

gastric adenocarcinoma

Therapies

Bevacizumab + Capecitabine + Carboplatin

Age Groups: adult

No variant requirements are available.